PBCAR269A

Overview

PBCAR269A is a BCMA targeted allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.

SparkCures ID 368
Developed By Precision BioSciences, Inc.
Generic Name PBCAR269A
Treatment Classifications
Treatment Targets

Clinical Trials

Resources